- Home
- RGEN vs AXSM Comparison
RGEN vs AXSM Comparison
Compare RGEN & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGEN
- AXSM
- Stock Information
- Founded
- RGEN 1981
- AXSM 2012
- Country
- RGEN United States
- AXSM United States
- Employees
- RGEN N/A
- AXSM N/A
- Industry
- RGEN Medical/Dental Instruments
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- RGEN Health Care
- AXSM Health Care
- Exchange
- RGEN Nasdaq
- AXSM Nasdaq
- Market Cap
- RGEN 6.5B
- AXSM 5.9B
- IPO Year
- RGEN N/A
- AXSM 2015
- Fundamental
- Price
- RGEN $145.83
- AXSM $118.28
- Analyst Decision
- RGEN Buy
- AXSM Strong Buy
- Analyst Count
- RGEN 11
- AXSM 19
- Target Price
- RGEN $167.90
- AXSM $174.26
- AVG Volume (30 Days)
- RGEN 929.7K
- AXSM 472.6K
- Earning Date
- RGEN 11-11-2025
- AXSM 11-03-2025
- Dividend Yield
- RGEN N/A
- AXSM N/A
- EPS Growth
- RGEN N/A
- AXSM N/A
- EPS
- RGEN N/A
- AXSM N/A
- Revenue
- RGEN $673,956,000.00
- AXSM $495,033,000.00
- Revenue This Year
- RGEN $16.77
- AXSM $63.62
- Revenue Next Year
- RGEN $13.79
- AXSM $55.72
- P/E Ratio
- RGEN N/A
- AXSM N/A
- Revenue Growth
- RGEN 8.73
- AXSM 69.83
- 52 Week Low
- RGEN $102.97
- AXSM $75.56
- 52 Week High
- RGEN $182.52
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- RGEN 68.33
- AXSM 52.00
- Support Level
- RGEN $121.25
- AXSM $117.60
- Resistance Level
- RGEN $125.90
- AXSM $122.14
- Average True Range (ATR)
- RGEN 5.31
- AXSM 3.15
- MACD
- RGEN 2.79
- AXSM -0.28
- Stochastic Oscillator
- RGEN 84.15
- AXSM 36.43
About RGEN Repligen Corporation
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.